SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Clinicopathological and prognostic significance of hypoxia-inducible factor-1α in esophageal squamous cell carcinoma: a meta-analysis.
Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review.Chinese journal of cancer · 2017Pooled it
- Elevated Tumor HIF-1α Expression Correlates with Advanced Pathological Stage Following Neoadjuvant Concurrent Chemoradiotherapy in Esophageal Squamous Cell Carcinoma.Current issues in molecular biology · 2026Article
- Low GATA3 predicts worse survival in penile cancer.Scientific reports · 2025Article
- Prognostic impact of the combination of HIF‑1α and GLUT1 in patients with oesophageal squamous cell carcinoma.Oncology letters · 2023Article
- A cross-sectional study of obstructive sleep apnea in patients with colorectal cancer.Journal of gastrointestinal oncology · 2022Article
- Prognostic value of HIF-1α in digestive system malignancies: evidence from a systematic review and meta-analysis.Gastroenterology and hepatology from bed to bench · 2022Article
- The essential role of PRAK in tumor metastasis and its therapeutic potential.Nature communications · 2021Article
- Manganese Porphyrin and Radiotherapy Improves Local Tumor Response and Overall Survival in Orthotopic Murine Mammary Carcinoma Models.Radiation research · 2021Article
- Esophageal Microenvironment: From Precursor Microenvironment to Premetastatic Niche.Cancer management and research · 2020Review
- Therapeutic Strategies Against Cancer Stem Cells in Esophageal Carcinomas.Frontiers in oncology · 2020Review
- Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma.World journal of surgical oncology · 2018Article
- Hypoxia imaging withRadiation oncology (London, England) · 2018Article
- A novel small-molecule arylsulfonamide causes energetic stress and suppresses breast and lung tumor growth and metastasis.Oncotarget · 2017Article
- Hypoxia and Bone Metastatic Disease.Current osteoporosis reports · 2017Review
- Inhibition of HIF-1α by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo.American journal of cancer research · 2017Article
- Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2016Article
- Hypoxia: Signaling the Metastatic Cascade.Trends in cancer · 2016Review
- Hypoxic control of metastasis.Science (New York, N.Y.) · 2016Review
- Prognostic role of hypoxia-inducible factor-1 alpha expression in osteosarcoma: a meta-analysis.OncoTargets and therapy · 2016Article
- Prognosis value of Hypoxia-inducible factor-1α expression in patients with bone and soft tissue sarcoma: a meta-analysis.SpringerPlus · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Published literatures on the prognostic value of hypoxia-inducible factor-1α (HIF-1α) overexpression in esophageal squamous cell carcinoma (ESCC) are conflicting and heterogeneous. We performed a meta-analysis to more precisely evaluate the clinicopathological and prognostic value of HIF-1α in patients with ESCC. Searches were applied to MEDLINE, Pubmed, Embase, Cochrane Library, Web of Science, and Chinese BioMedical Literature Databases until September 10, 2013, without language restrictions. The pooled hazard ratios (HRs) and odds ratios (ORs) with corresponding 95 % confidence intervals (CIs) were used to estimate the effects. Twelve studies with 942 ESCC patients were selected to evaluate the correlation between HIF-1α and overall survival (OS), disease-free survival (DFS), response to chemoradiation (RC), and clinicopathological features. HIF-1α overexpression was significantly associated with poor OS (HR 1.78, 95% CI 1.41-2.24), DFS (HR 1.91, 95% CI 1.15-3.18), and RC (HR 3.56, 95% CI 1.68-7.53). Besides, HIF-1α overexpression was significantly associated with stage (OR 2.90, 95% CI 1.97-4.27), lymph node metastasis (OR 1.86, 95% CI 1.39-2.49), depth of invasion (OR 2.45, 95% CI 1.24-4.86), lymphatic invasion (OR 2.28, 95% CI 1.46-3.56), distant metastasis (OR 2.04, 95% CI 1.19-3.50), and vascular endothelial growth factor (OR 3.67, 95% CI 1.81-7.46). Our results indicate that HIF-1α overexpression can potently predict the poor prognosis and chemoradiation resistance for ESCC. Large prospective studies with multivariable survival analyses are now needed to confirm the clinical utility of HIF-1α as an independent prognostic marker.
Indexed as
Identifiers
24425106What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.